<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01026116</url>
  </required_header>
  <id_info>
    <org_study_id>SHBCC09007</org_study_id>
    <nct_id>NCT01026116</nct_id>
  </id_info>
  <brief_title>A Randomized Trial Comparing EC-wPversus EP-wP as Adjuvant Therapy for Operable Breast Cancer Patients Less Than 40 Years Old</brief_title>
  <official_title>Comparing EC-wP Versus EP-wP as Adjuvant Therapy for Breast Cancer Patients Less Than 40 Years Old</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Manifold data revealed that young breast cancer patients are characterized by aggressive
      clinical history. The purpose of this study is to evaluate the efficacy and safety of
      different strategies incorporating paclitaxel to anthracycline-based regimens in young breast
      cancer patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">December 23, 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>every one year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>menstrual resumption rate</measure>
    <time_frame>12 months after chemotherapy</time_frame>
    <description>Resumption of menses was defined as at least 2 consecutive menstruations, or at least 1 menstruation with a confirmed premenopausal level of FSH and estradiol after chemotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>every one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">521</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>EC-wP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>epirubicin/cyclophosphamide followed weekly paclitaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EP-wP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>epirubicin/paclitaxel followed by weekly paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <description>75 mg/m2 every-3-week for four cycles</description>
    <arm_group_label>EC-wP</arm_group_label>
    <arm_group_label>EP-wP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>600 mg/m2 every-3-week for four cycles</description>
    <arm_group_label>EC-wP</arm_group_label>
    <arm_group_label>EP-wP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>175 mg/m2 every-3-week for four cycles followed by weekly paclitaxel (80 mg/m2) for 12 weeks</description>
    <arm_group_label>EC-wP</arm_group_label>
    <arm_group_label>EP-wP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients, age 18~40

          -  Unilateral, operable, histologically confirmed adenocarcinoma of the breast

          -  Stage I-III

          -  Primary surgery with clear margins plus axillary dissection

          -  Able to start protocol Rx within 8 weeks of surgery

          -  Histological or cytological confirmation of estrogen-receptor positive (ER+) breast
             cancer: the immunohistochemical cut-off for ER positive status was

             1% or more staining in nuclei

          -  HER-2 negative (IHC 0,1+ or 2+ with a negative in situ hybridization test by
             chemotherapy

          -  pathologically confirmed regional node-positive disease, or node-negative disease with
             high-risk factors (primary tumor diameter &gt;10 mm when histological grade III, or tumor
             diameter &gt;20 mm when histological grade II)

          -  ECOG performance status 0-1

          -  Adequate cardiac, renal, hepatic and hematologic function

        Exclusion Criteria:

          -  Metastatic disease

          -  Bilateral breast cancer (synchronous or metachronous)

          -  Prior radiation therapy, hormonal therapy and chemotherapy for breast cancer

          -  Previous cancer (except treated basal cell and squamous cell carcinoma of the skin or
             cancer of the uterine cervix)

          -  HER-2 positive (IHC 3+ OR FISH+) and or triple-negative breast cancer

          -  Documented history of cardiac disease contradiction anthracyclines

          -  Concurrent serious illness

          -  Peripheral neuropathy of CTC grade&gt;1

          -  History of hypersensitivity to drugs formulated in Cremophor EL polyoxyethylated
             castor oil), the vehicle used for commercial paclitaxel formulations

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhimin Shao</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Hospital, Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Breast Surgery, Cancer Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>December 3, 2009</study_first_submitted>
  <study_first_submitted_qc>December 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2009</study_first_posted>
  <last_update_submitted>May 9, 2020</last_update_submitted>
  <last_update_submitted_qc>May 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Zhimin Shao</investigator_full_name>
    <investigator_title>Director of Breast Surgery Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

